Neuropace Inc (NPCE)
Healthcare
Medical Devices
—
12.90 $
-6.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Neuropace Inc (NPCE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -11 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -25 | -22 | -25 | -37 | -20 | -18 | -11 | |
| 0.4 | 0.3 | 0.3 | 3.0 | 1.6 | 1.8 | 1.9 | |
| 1.4 | 1.4 | 4.3 | 8.3 | 9.6 | 10 | 11 | |
| 2.1 | 0.9 | 9.8 | 11 | – | – | – | |
| 0.0 | -2.1 | 0.4 | -4.8 | -2.5 | -5.5 | -4.0 | |
| 0.5 | 0.1 | 0.4 | 0.6 | 0.2 | 0.3 | 0.3 | |
| 3.6 | -11 | -85 | 24 | 23 | 9.0 | -0.3 | |
| – | – | 107 | -0.1 | -0.3 | 0.0 | -50 | |
| 21 | 24 | -4.1 | 0.0 | – | 0.0 | -2.1 | |
| 21 | 55 | 103 | 0.5 | 8.1 | 4.3 | 20 | |
| 0.0 | 23 | -7.4 | -13 | 11 | -4.6 | 8.3 | |
| -25 | -22 | -25 | -37 | -20 | -18 | -11 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.